Etsushi Kawamura

Dr. Etsushi Kawamura

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EKEtsushi Kawamura
Etsushi Kawamura
TMTsutomu Matsubara
Tsutomu Matsubara
NKNorifumi Kawada
Norifumi Kawada
Intrahepatic cholangiocarcinoma (CC) accounts for approximately 20% of all biliary tract cancer (BTC) cases and 10–15% of all primary liver cancer cases. Many patients are diagnosed with unresectable BTC, and, even among patients with resectable BTC, the 5-year survival rate is approximately 20%. The BTC incidence rate is high in Southeast and East Asia and has increased worldwide in recent years. Since 2010, cytotoxic chemotherapy, particularly combination gemcitabine + cisplatin (ABC-02 trial), has been the first-line therapy for patients with BTC. In 2022, a multicenter, double-blind, randomized phase 3 trial (TOPAZ-1 trial) examined the addition of programmed death-ligand 1 immunotherapy (durvalumab) to combination gemcitabine + cisplatin for BTC treatment, resulting in significantly improved survival without notable additional toxicity. As a result of this trial, this three-drug combination has become the new standard first-line therapy, leading to notable advances in BTC management for the first time since 2010. The molecular profiling of BTC has continued to drive the development of new targeted therapies for use when first-line therapies fail. Typically, second-line therapy decisions are based on identified genomic alterations in tumor tissue. Mutations in fibroblast growth factor receptor 1/2/3, isocitrate dehydrogenase 1/2, and neurotrophic tyrosine receptor kinase A/B/C are relatively frequent in intrahepatic CC, and precision medicines are available that can target associated pathways. In this review, we suggest strategies for systemic pharmacotherapy with a focus on intrahepatic CC, in addition to presenting the results and safety outcomes of clinical trials evaluating immune checkpoint inhibitor therapies in BTC.

26 February 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
YMYoshinari Matsumoto
Yoshinari Matsumoto
HFHideki Fujii
Hideki Fujii
MHMika Harima
Mika Harima
HOHaruna Okamura
Haruna Okamura
YYYoshimi Yukawa-Muto
Yoshimi Yukawa-Muto
NKNorifumi Kawada
Norifumi Kawada
It is not fully clear as to which dietary patterns are associated with the pathogenesis of nonalcoholic fatty liver disease (NAFLD) in Asia. We conducted a cross-sectional study of 136 consecutively recruited patients with NAFLD (49% female, median age 60 years). Severity of liver fibrosis was assessed using the Agile 3+ score, a recently proposed system based on vibration-controlled transient elastography. Dietary status was assessed using the 12-component modified Japanese diet pattern index (mJDI12). Skeletal muscle mass was assessed by bioelectrical impedance. Factors associated with intermediate–high-risk Agile 3+ scores and skeletal muscle mass (75th percentile or higher) were analyzed by multivariable logistic regression. After adjustment for confounders, such as age and sex, the mJDI12 (OR: 0.77; 95% CI: 0.61, 0.99) and skeletal muscle mass (75th percentile or higher) (OR: 0.23; 95% CI: 0.07, 0.77) were significantly associated with intermediate–high-risk Agile 3+ scores. Soybeans and soybean foods were significantly associated with skeletal muscle mass (75th percentile or higher) (OR: 1.02; 95% CI: 1.00, 1.04). In conclusion, the Japanese diet pattern was associated with the severity of liver fibrosis in Japanese patients with NAFLD. Skeletal muscle mass was also associated with the severity of liver fibrosis, and intake of soybeans and soybean foods.

1 January 2013 in Internal Medicine
Verified
Journal Article
Open access
PDF file
AHAtsushi Hagihara
Atsushi Hagihara
YTYuga Teranishi
Yuga Teranishi
EKEtsushi Kawamura
Etsushi Kawamura
HFHideki Fujii
Hideki Fujii
SIShuji Iwai
Shuji Iwai
NKNorifumi Kawada
Norifumi Kawada
The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.

1 January 2007 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AOAi Oe
Ai Oe
JKJoji Kawabe
Joji Kawabe
KTKenji Torii
Kenji Torii
EKEtsushi Kawamura
Etsushi Kawamura
JKJin Kotani
Jin Kotani
SSSusumu Shiomi
Susumu Shiomi

26 September 2022 in FEBS Open Bio
Verified
Journal Article
Open access
EKEtsushi Kawamura
Etsushi Kawamura
TMTsutomu Matsubara
Tsutomu Matsubara
ADAtsuko Daikoku
Atsuko Daikoku
SDSanae Deguchi
Sanae Deguchi
MKMasahiko Kinoshita
Masahiko Kinoshita
NKNorifumi Kawada
Norifumi Kawada
Cholangiocarcinoma (CC) has a poor prognosis and different driver genes depending on the site of onset. Intrahepatic CC is the second‐most common liver cancer after hepatocellular carcinoma, and novel therapeutic targets are urgently needed. The present study was conducted to identify novel therapeutic targets by exploring differentially regulated genes in human CC. MicroRNA (miRNA) and mRNA microarrays were performed using tissue and serum samples obtained from 24 surgically resected hepatobiliary tumor cases, including 10 CC cases. We conducted principal component analysis to identify differentially expressed miRNA, leading to the identification of miRNA‐3648 as a differentially expressed miRNA. We used an in silico screening approach to identify its target mRNA, the tumor suppressor Sloan Kettering Institute (SKI). SKI protein expression was decreased in human CC cells overexpressing miRNA‐3648, endogenous SKI protein expression was decreased in human CC tumor tissues, and endogenous SKI mRNA expression was suppressed in human CC cells characterized by rapid growth. SKI‐overexpressing OZ cells (human intrahepatic CC cells) showed upregulation of cyclin‐dependent kinase inhibitor p21 mRNA and protein expression and suppressed cell proliferation. Nuclear expression of CDT1 (chromatin licensing and DNA replication factor 1), which is required for the G1/S transition, was suppressed in SKI‐overexpressing OZ cells. SKI knockdown resulted in the opposite effects. Transgenic p21‐luciferase was activated in SKI‐overexpressing OZ cells. These data indicate SKI involvement in p21 transcription and that SKI–p21 signaling causes cell cycle arrest in G1, suppressing intrahepatic CC cell growth. Therefore, SKI may be a potential therapeutic target for intrahepatic CC.

4 August 2025 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HFHideki Fujii
Hideki Fujii
SUSawako Uchida‑Kobayashi
Sawako Uchida‑Kobayashi
AKAtsushi Kanamori
Atsushi Kanamori
YNYuji Nadatani
Yuji Nadatani
EKEtsushi Kawamura
Etsushi Kawamura
TWToshio Watanabe
Toshio Watanabe